NEW YORK (GenomeWeb) – Agena Bioscience and Horizon Discovery announced today that they have signed an agreement to incorporate Horizon's human genomic reference standards into oncology-based assays run on Agena's MassArray system.
Through the partnership, Agena will offer multiplexed sets of iPlex-branded reference standards containing somatic variants in key oncogenic genes implicated in colon, lung, and skin cancers. The standards will be made from cell lines created using Horizon's proprietary genome engineering platform and will be provided at fixed and known allelic frequencies in order to mimic actual patient tumors, the companies said.
Additional terms of the arrangement were not disclosed.
"We are committed to accelerating the development and deployment of clinical research tests on the MassArray system," Agena CEO Pete Dansky said in a statement. "This development of standards for Agena Bioscience by Horizon will provide a cost-effective, optimized resource for efficient test deployment."
The deal with Agena marks the latest that Horizon has inked for its reference standards in recent months. Last year, the company signed agreements with Swift Biosciences, Bioké, and CareDx.